Moncef Slaoui, a former pharmaceutical executive now heading the Trump administration's coronavirus vaccine task force, Operation Warp Speed, does not have to disclose or divest his investments in the industry.
He is the former head of GlaxoSmithKline's (GSK) vaccines department continues to hold stock in the company, even as it is collaborating with Sanofi on a potential vaccine.
In addition to holding $10 million in stock in GSK as of May, Slaoui held an unknown number of shares in the company when he took the Operation Warp Speed position.
Slaoui is also chairman of the board of research company Vaxcyte. The company has received investment from Medicxi, a venture capital firm from which Slaoui is currently on hiatus as a partner.
He is free to hold and acquire financial interests in the same vaccine companies to which he is helping award government contracts. It is a blatant conflict of interest.
https://www.commondreams.org/news/2020/07/15/defying-logic-and-law-hhs-inspector-general-allows-trumps-vaccine-czar-maintain-big
He is the former head of GlaxoSmithKline's (GSK) vaccines department continues to hold stock in the company, even as it is collaborating with Sanofi on a potential vaccine.
In addition to holding $10 million in stock in GSK as of May, Slaoui held an unknown number of shares in the company when he took the Operation Warp Speed position.
Slaoui is also chairman of the board of research company Vaxcyte. The company has received investment from Medicxi, a venture capital firm from which Slaoui is currently on hiatus as a partner.
He is free to hold and acquire financial interests in the same vaccine companies to which he is helping award government contracts. It is a blatant conflict of interest.
https://www.commondreams.org/news/2020/07/15/defying-logic-and-law-hhs-inspector-general-allows-trumps-vaccine-czar-maintain-big
No comments:
Post a Comment